TriangleJNJ-90301900 (NCT06667908)
JNJ-90301900 trial for Carcinoma, Non-Small-Cell Lung (NCT06667908). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recently diagnosed, unresectable stage III non-small-cell lung cancer. A tumor or involved lymph node must be suitable for injection and radiation.
The idea: add JNJ-90301900 injections directly into tumors or lymph nodes to carboplatin, paclitaxel and radiation, followed by durvalumab. Durvalumab blocks PD-L1, which can release a brake on immune-cell attack. Early groups test injection feasibility. Later groups compare two injection levels against treatment without JNJ-90301900. Researchers measure tumor response and safety.
This phase 2 study plans 130 patients. Johnson & Johnson sponsors seventeen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.